Bedi S S
Curr Med Res Opin. 1975;3(5):309-20. doi: 10.1185/03007997509114781.
A double-blind trial was carried out in 76 patients with active rheumatoid arthritis to compare the analgesic and anti-inflammatory activity of 3 g. alclofenac with 4.8 g. aspirin daily over a 6-week period. All patients selected showed reversible inflammatory swelling of the finger joints. Of the 60 patients successfully completing the trial, 30 were treated as out-patients and 30 patients received in-patient treatment for approximately the first 2 weeks. Both groups were analysed separately. Treatment was randomised and patients received the drugs in identical tablet form except for the last 16 patients who were transferred to capsules. Results showed that though the activity potential, morning stiffness, grip strength, joint pain and tenderness improved significantly at the end of the 6-week period, there was no statistical difference between the two drugs. However, functional capacity indicated slight superiority of alclofenac over aspirin at a low level of significance. P.I.P. joint swelling showed that both in-patients and out-patients on alclofenac improved significantly (p less than .001)compared to patients in the aspirin group. Laboratory investigations showed no difference between the two drugs as far as changes in serum proteins, serum transaminase, haemoglobin and E.S.R. levels were concerned. However, serum uric acid levels dropped significantly (.05 greater than p greater than .01) with aspirin. The incidence of side-effects was slightly higher in the aspirin group but a high incidence of skin rash (30% approx.) was recorded with alclofenac tablets. No incidence of skin rash was recorded in patients taking alclofenac capsules, but the number of patients taking capsules was too small to make any prediction. It appears from this study that in active rheumatoid arthritis the analgesic and anti-inflammatory activity of 3 g. alclofenac is equivalent to 4.8 g. aspirin, and alclofenac is superior to aspirin in reducing the inflammatory swelling of rheumatoid joints.
对76例活动性类风湿性关节炎患者进行了一项双盲试验,比较每日3克阿氯芬酸与4.8克阿司匹林在6周期间的镇痛和抗炎活性。所有入选患者均表现出手指关节可逆性炎症肿胀。在成功完成试验的60例患者中,30例作为门诊患者接受治疗,30例患者在前两周左右接受住院治疗。两组分别进行分析。治疗是随机的,除了最后16例转为服用胶囊的患者外,患者均以相同的片剂形式接受药物治疗。结果显示,尽管在6周结束时,活动潜能、晨僵、握力、关节疼痛和压痛均有显著改善,但两种药物之间没有统计学差异。然而,功能能力表明阿氯芬酸在低显著水平上略优于阿司匹林。近端指间关节肿胀显示,与阿司匹林组患者相比,服用阿氯芬酸的住院患者和门诊患者均有显著改善(p小于0.001)。实验室检查表明,就血清蛋白、血清转氨酶、血红蛋白和血沉水平的变化而言,两种药物之间没有差异。然而,服用阿司匹林后血清尿酸水平显著下降(0.05大于p大于0.01)。阿司匹林组的副作用发生率略高,但阿氯芬酸片剂的皮疹发生率较高(约30%)。服用阿氯芬酸胶囊的患者未记录到皮疹发生率,但服用胶囊的患者数量太少,无法做出任何预测。从这项研究看来,在活动性类风湿性关节炎中,3克阿氯芬酸的镇痛和抗炎活性相当于4.8克阿司匹林,并且阿氯芬酸在减轻类风湿关节的炎症肿胀方面优于阿司匹林。